Sanara MedTech Q1 Revenue Up 19%, Shares Rise 22%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Last night, the company also reported Q1 revenue $27.8M vs. $23.4M last year. Seth Yon, CEO, commented, "The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We're particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down. During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps. Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than 450 distributors. Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth." Shares of Sanara MedTech are up 22% in pre-market at $22.04.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 21.260
Low
36.00
Averages
36.00
High
36.00
Current: 21.260
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanara MedTech Under Investigation for Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program, aiming to reallocate resources to its core surgical business to enhance operational efficiency; however, this move has led to significant financial losses for the company.
- Financial Loss Disclosure: In its Q3 2025 financial report, Sanara revealed a net loss of $31.2 million from discontinued operations, with $26.5 million attributed to a noncash asset impairment charge, directly reflecting the negative financial impact of shutting down the THP program.
- Stock Price Volatility: Following the announcement of the THP program's discontinuation, Sanara's stock price plummeted by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, indicating market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, highlighting potential legal risks facing the company.
See More
Pomerantz Investigates Sanara MedTech for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) program, aimed at reallocating resources to its core surgical business to enhance operational efficiency; however, this decision has led to significant financial losses for the company.
- Financial Loss Disclosure: In its subsequent earnings report, Sanara reported a net loss from discontinued operations of $31.2 million, with a $26.5 million noncash asset impairment charge directly tied to the closure of the THP program, highlighting the substantial financial burden this project imposed on the company.
- Stock Price Plummet: Following the announcement of the operational halt, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, reflecting market pessimism regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, indicating potential legal risks facing the company.
See More
Sanara MedTech Under Investigation for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, aiming to enhance operational efficiency; however, this move has led to significant financial losses for the company.
- Financial Loss Disclosure: In its Q3 2025 financial report, Sanara revealed a net loss of $31.2 million from discontinued operations, which included a $26.5 million non-cash asset impairment charge directly tied to the closure of the THP program, indicating substantial financial pressure during the transition.
- Stock Price Volatility: Following the announcement of the THP program's discontinuation, Sanara's stock price plummeted by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, reflecting market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, highlighting the increasing legal risks faced by the company.
See More
Sanara MedTech Reports Strong Q1 2026 Earnings with 19% Revenue Growth
- Significant Revenue Growth: Sanara MedTech reported a $4.4 million revenue increase in Q1 2026, reflecting a 19% year-over-year growth, which underscores the company's strategic focus on the surgical market and enhances its competitive position.
- Improved Profitability: The company achieved GAAP net income of $0.4 million, translating to $0.04 per diluted share, with gross margins rising to 93%, indicating successful sales and market penetration strategies that strengthen its financial foundation.
- Sales Network Expansion: By the end of the quarter, Sanara had 43 sales representatives, with products contracted or approved for sale in over 4,000 hospitals and ambulatory surgery centers, showcasing the company's strong market presence and distribution capabilities.
- Optimistic Outlook: Management expects Q2 net revenue to range between $28.5 million and $29.5 million, representing a year-over-year growth of 10% to 14%, while reaffirming full-year net revenue guidance of $116 million to $121 million, reflecting confidence in future growth.
See More
Sanara MedTech Under Investigation for Securities Violations Impacting Shareholder Rights
- Legal Investigation Launched: The Schall Law Firm has initiated an investigation into Sanara MedTech, focusing on potential violations of securities laws that may harm shareholder rights, indicating possible issues with the company's transparency and compliance.
- Business Adjustment Impact: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, claiming the decision was made to reallocate resources to its core surgical business; however, this move may reflect underlying inefficiencies in the company's operations.
- Significant Financial Losses: In its Q3 2025 financial report, Sanara disclosed a net loss of $31.2 million from discontinued operations, including a $26.5 million charge related to the THP program, highlighting challenges in financial management and operational viability.
- Stock Price Plummet: Following the news, Sanara's shares fell by 24.7% on November 12, 2026, reflecting market pessimism regarding the company's future prospects, which could adversely affect its ability to raise capital and investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Sanara MedTech
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Sanara MedTech and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially lead to a class action lawsuit.
- Business Restructuring Decision: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, with management stating that this move was intended to reallocate resources to its core surgical business to enhance operational efficiency.
- Financial Loss Disclosure: Following the cessation of the THP program, Sanara reported a net loss of $31.2 million for Q3 2025, including a $26.5 million non-cash asset impairment charge directly related to the program's shutdown, highlighting the financial impact of the business adjustment.
- Stock Price Volatility: After the loss announcement on November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, reflecting market concerns regarding the company's future outlook.
See More
Sanara MedTech Under Investigation for Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program, aiming to reallocate resources to its core surgical business to enhance operational efficiency; however, this move has led to significant financial losses for the company.
- Financial Loss Disclosure: In its Q3 2025 financial report, Sanara revealed a net loss of $31.2 million from discontinued operations, with $26.5 million attributed to a noncash asset impairment charge, directly reflecting the negative financial impact of shutting down the THP program.
- Stock Price Volatility: Following the announcement of the THP program's discontinuation, Sanara's stock price plummeted by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, indicating market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, highlighting potential legal risks facing the company.
See More
Pomerantz Investigates Sanara MedTech for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) program, aimed at reallocating resources to its core surgical business to enhance operational efficiency; however, this decision has led to significant financial losses for the company.
- Financial Loss Disclosure: In its subsequent earnings report, Sanara reported a net loss from discontinued operations of $31.2 million, with a $26.5 million noncash asset impairment charge directly tied to the closure of the THP program, highlighting the substantial financial burden this project imposed on the company.
- Stock Price Plummet: Following the announcement of the operational halt, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, reflecting market pessimism regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, indicating potential legal risks facing the company.
See More
Sanara MedTech Under Investigation for Securities Fraud
- Operational Cessation Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, aiming to enhance operational efficiency; however, this move has led to significant financial losses for the company.
- Financial Loss Disclosure: In its Q3 2025 financial report, Sanara revealed a net loss of $31.2 million from discontinued operations, which included a $26.5 million non-cash asset impairment charge directly tied to the closure of the THP program, indicating substantial financial pressure during the transition.
- Stock Price Volatility: Following the announcement of the THP program's discontinuation, Sanara's stock price plummeted by $6.93, or 24.7%, closing at $21.11 on November 12, 2025, reflecting market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Sanara and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action, highlighting the increasing legal risks faced by the company.
See More
Sanara MedTech Reports Strong Q1 2026 Earnings with 19% Revenue Growth
- Significant Revenue Growth: Sanara MedTech reported a $4.4 million revenue increase in Q1 2026, reflecting a 19% year-over-year growth, which underscores the company's strategic focus on the surgical market and enhances its competitive position.
- Improved Profitability: The company achieved GAAP net income of $0.4 million, translating to $0.04 per diluted share, with gross margins rising to 93%, indicating successful sales and market penetration strategies that strengthen its financial foundation.
- Sales Network Expansion: By the end of the quarter, Sanara had 43 sales representatives, with products contracted or approved for sale in over 4,000 hospitals and ambulatory surgery centers, showcasing the company's strong market presence and distribution capabilities.
- Optimistic Outlook: Management expects Q2 net revenue to range between $28.5 million and $29.5 million, representing a year-over-year growth of 10% to 14%, while reaffirming full-year net revenue guidance of $116 million to $121 million, reflecting confidence in future growth.
See More
Sanara MedTech Under Investigation for Securities Violations Impacting Shareholder Rights
- Legal Investigation Launched: The Schall Law Firm has initiated an investigation into Sanara MedTech, focusing on potential violations of securities laws that may harm shareholder rights, indicating possible issues with the company's transparency and compliance.
- Business Adjustment Impact: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, claiming the decision was made to reallocate resources to its core surgical business; however, this move may reflect underlying inefficiencies in the company's operations.
- Significant Financial Losses: In its Q3 2025 financial report, Sanara disclosed a net loss of $31.2 million from discontinued operations, including a $26.5 million charge related to the THP program, highlighting challenges in financial management and operational viability.
- Stock Price Plummet: Following the news, Sanara's shares fell by 24.7% on November 12, 2026, reflecting market pessimism regarding the company's future prospects, which could adversely affect its ability to raise capital and investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Sanara MedTech
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Sanara MedTech and its executives have engaged in securities fraud or other unlawful business practices, aiming to protect investor rights and potentially lead to a class action lawsuit.
- Business Restructuring Decision: On November 11, 2025, Sanara announced the discontinuation of its Tissue Health Plus program, with management stating that this move was intended to reallocate resources to its core surgical business to enhance operational efficiency.
- Financial Loss Disclosure: Following the cessation of the THP program, Sanara reported a net loss of $31.2 million for Q3 2025, including a $26.5 million non-cash asset impairment charge directly related to the program's shutdown, highlighting the financial impact of the business adjustment.
- Stock Price Volatility: After the loss announcement on November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, reflecting market concerns regarding the company's future outlook.
See More
